Mayne Pharma GroupMAYNF 52 Cyclically Adjusted PS Ratio is 0.43 as of Jul. 11, 2026, which is 60% below its 10-year median of 1.08. GuruFocus rates MAYNF with a GF Score™ of 52/100 and a GF Value™ of $3.70 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 89 Medical Distribution companies, Mayne Pharma Group ranks worse than 55.06% on this metric.
The historical rank and industry rank for Mayne Pharma Group's Cyclically Adjusted PS Ratio or its related term are showing as below:
MAYNF'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.32 Med: 1.08 Max: 8.71
Current: 0.42
During the past 13 years, Mayne Pharma Group's highest Cyclically Adjusted PS Ratio was 8.71. The lowest was 0.32. And the median was 1.08.
MAYNF's Cyclically Adjusted PS Ratio is ranked worse than 55.06% of 89
companies
in the Medical Distribution industry
Industry Median: 0.37
vs MAYNF: 0.42
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Mayne Pharma Group's adjusted revenue per share data of for the fiscal year that ended in Jun25 was $3.344. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $4.54 for the trailing ten years ended in Jun25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Mayne Pharma Group (OTCPK:MAYNF) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Mayne Pharma Group Cyclically Adjusted PS Ratio Related Terms
Mayne Pharma Group Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayne Pharma Group Cyclically Adjusted PS Ratio Chart
MAYNF vs MCK, CAH, COR: Cyclically Adjusted PS Ratio Comparison
For the Medical Distribution subindustry, Mayne Pharma Group's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group Cyclically Adjusted PS Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's Cyclically Adjusted PS Ratio falls into.
Mayne Pharma Group Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Mayne Pharma Group's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 0.43 mean?
Mayne Pharma Group (MAYNF) has a Cyclically Adjusted PS Ratio of 0.43 as of Jul. 11, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Mayne Pharma Group and its competitors. This is 60% below median its historical median of 1.08. Over the past decade, Mayne Pharma Group's Cyclically Adjusted PS Ratio has ranged from 0.32 to 8.71. According to the industry distribution chart, Mayne Pharma Group ranks #49 out of 89 companies in the Medical Distribution industry, placing it in the top 55.1%.
Is Mayne Pharma Group's Cyclically Adjusted PS Ratio too high?
Mayne Pharma Group's current Cyclically Adjusted PS Ratio of 0.43 is 60% below median its 10-year median of 1.08. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 8.71. The Medical Distribution industry median Cyclically Adjusted PS Ratio is 0.37. Mayne Pharma Group's value of 0.43 is 16.2% above this industry median. Based on the distribution chart, Mayne Pharma Group ranks #49 out of 89 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Mayne Pharma Group has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Cyclically Adjusted PS Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #49 out of 89 companies for Cyclically Adjusted PS Ratio. This places Mayne Pharma Group in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 0.37. Mayne Pharma Group's value of 0.43 is 16.2% above this benchmark. Historically, Mayne Pharma Group's own Cyclically Adjusted PS Ratio has ranged from 0.32 to 8.71 over the past decade. While the company's 10-year median is 1.08 vs. the industry median of 0.37, Mayne Pharma Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Distribution company?
The median Cyclically Adjusted PS Ratio among Medical Distribution companies is 0.37, based on 89 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mayne Pharma Group's current Cyclically Adjusted PS Ratio of 0.43 is 16.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median Cyclically Adjusted PS Ratio is 0.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current Cyclically Adjusted PS Ratio is 0.43, which is 60% below median its own 10-year median of 1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.70, compared to a current price of $1.97 — trading 46.7% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 0.43, which is 60% below median its 10-year median of 1.08 and 16.2% above the Medical Distribution industry median of 0.37. Mayne Pharma Group's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current Cyclically Adjusted PS Ratio is 0.43 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (MAYNF) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of $1.97 is trading 46.7% below its estimated GF Value™ of $3.70.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for MAYNF:
Cyclically Adjusted PS Ratio: 0.43 (60% below median its 10-year median of 1.08)
GF Value™: $3.70 vs. price of $1.97 (46.7% below fair value)
Industry Position: 16.2% above the Medical Distribution median (#49 of 89)
No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
52GF Score
Get the complete analysis for MAYNF
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAYNF has been successfully added to your 
